NCT05099822View on ClinicalTrials.gov

Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of CC-97489 in Healthy Adult Participants

PHASE1TerminatedINTERVENTIONAL
Enrollment

84

Participants

Timeline

Start Date

March 13, 2020

Primary Completion Date

July 11, 2022

Study Completion Date

July 11, 2022

Conditions
Healthy Volunteers
Interventions
DRUG

CC-97489

Specified dose on specified days

OTHER

Placebo

Specified dose on specified days

Trial Locations (1)

3000

Local Institution - 001, Leuven

Sponsors

Lead Sponsor

Celgene
All Listed Sponsors
lead

Celgene

INDUSTRY